Related Experiment Videos

Most of the patients presenting myocardial infarction would not be eligible for intensive lipid-lowering based on

Andrei C Sposito1, Bruno Farah Alvarenga, Alison S Alexandre

  • 1Faculty of Medical Sciences, State University of Campinas, Campinas, SP, Brazil. dclandrei@yahoo.com

Atherosclerosis
|December 1, 2010
PubMed

Insights

Current risk algorithms fail to identify many ST-elevation myocardial infarction (STEMI) patients for intensive lipid-lowering therapy. Adding anatomical measures like coronary artery calcium (CAC) and carotid plaques improves risk assessment for cardiovascular disease (CVD).

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Medical Imaging

Background:

  • Current cardiovascular disease (CVD) risk algorithms often underestimate risk in patients experiencing myocardial infarction (MI).
  • Guidelines for intensive lipid-lowering therapy may exclude a significant number of high-risk individuals.
  • Accurate risk stratification is crucial for effective preventive strategies.

Purpose of the Study:

  • To evaluate the effectiveness of existing risk scores in identifying ST-elevation MI (STEMI) patients eligible for intensive lipid-lowering therapy.
  • To determine if anatomical imaging markers can improve CVD risk assessment in STEMI patients.

Main Methods:

  • Assessed 355 STEMI patients using Framingham, PROCAM, Reynolds, ASSIGN, QRISK, and SCORE algorithms.
  • Measured admission C-reactive protein (CRP).
  • Utilized cardiac computed tomography for coronary artery calcium (CAC) scoring and carotid ultrasound for intima-media thickness (cIMT) and plaque assessment.

Main Results:

  • Less than 50% of STEMI patients were identified as high-risk by traditional algorithms prior to their event.
  • Traditional risk scores, except Framingham, assigned low risk to approximately half of the patients.
  • Combining CAC score (≥100) and carotid plaques identified 100% of patients as high-risk, regardless of the algorithm used.

Conclusions:

  • Over half of STEMI patients are inadequately assessed for intensive preventive therapy by current clinical algorithms.
  • Incorporating anatomical data, specifically CAC and carotid plaque presence, significantly enhances CVD risk stratification and reduces underestimation.
Abstract

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...